Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I haven't kept up with this name, but was curious as to how the Nasal Spray study in Irvine, CA was going...has anybody heard anything positive on that study? It seemed like it could be huge for the company if it plays out. Thanks.
Does anyone know many S19 Pro's CLSK has in full operation? Thx
Welcome. Nice close on MARA today,$29.48,up+1.87(+6.77%)
Adamizer, that is cool, thx. I got my feet wet too. LFG!
UTRX got a huge haircut today on heavy volume...low of the day was 0.113, closed at 0.142 - 40.58%, Vol 543K. Is it headed back to .05? Or is this a great DIP buy?
Accumulate AXXA! LFG
Chip should put out a flipping PR regarding the massive volume last Friday, the company owes its shareholders an explanation...unless of course there was insider buying and it leaked...if so, let's hope it will be different this time around and we get a BO offer, not like the insider selling just before J&J walked! LFG
June 21, 2021 7:37am
Compass Point Initiates Coverage On Marathon Digital Holdings with Buy Rating, Announces Price Target of $40
Benzinga Newdesk , Benzinga Staff Writer
Adamizer - Okay, great thank you.
Adamizer, I just discovered UTRX and starting my DD. I see it has a stop sign, do you know if the company has filed to go pink before September? Thanks.
GERN is just getting started now with the pain that will be served up to the subhuman shorts that have controlled this stock for years. P3 studies begin soon and when early data confirms even more of a reason the FDA should approve IMET, shorty is going to get vaporized!
If BTC hits $100K by year-end 2021, and if MARA's 103K miners are cha chinging 24/7 the stock price could fetch $200.00 based on generating $1B in NI and selling at a modest 20 PE.
ACCUMULATE on any dips if you can...IMO, MARA is a gift at today's $43.00 price.
All we need is an update from the company on future plans and MDMP rips to new highs. Also, if management is successful in proving out additional wells, this little gem will fetch $10.00+ later the year. Diamond hands here.
MDMP Management should host a call with shareholders to update them on their future drill/production plans. The stock has a lot of eyes on it and they should capitalize on that IMO!
MDMP is worth $4.89+ per share based on reserves in the ground and assets on the books. Trading at .81 is a flipping gift!
Does anyone know how many shares are outstanding? Thx
IMET+ RIZO + GOTTLIEB + KOL = $$$
Bank of New York Mellon Corp Buys 79,827 Shares of Geron Co. (NASDAQ:GERN)
Posted by Amelie Mason on Oct 10th,2019
Bank of New York Mellon Corp boosted its stake in Geron Co. (NASDAQ:GERN) by 11.0% in the 2nd quarter, Holdings Channel reports. The firm owned 805,331 shares of the biopharmaceutical company’s stock after acquiring an additional 79,827 shares during the quarter.
Anyone notice the volume spike and 15% gain yesterday with no news? All aboard!!
I am adding! Long term POTN should be a good one!
ICOTF shares getting bought in anticipation of good news!
Today's close: 0.1841+0.0344 (+22.98%) Vol 158,000
Press Release
iCo Therapeutics Provides Corporate Update, Announces Completion of Phase 1 Recruitment
Published: June 20, 2018 8:00 a.m. ET
Vancouver, British Columbia, Jun 20, 2018 (Newsfile Corp via COMTEX) -- iCo Therapeutics (ICO) (otcqb:ICOTF) ("iCo" or "the Company"), today announced the completion of recruitment of all 32 subjects in the Company's Phase 1 Oral Amphotericin B (Oral Amp B) study.
Phase 1 Oral Amp B Clinical Trial
The Phase 1 Australian study is a randomized, double-masked, placebo-controlled, single dose ascending study to assess the safety, tolerability, and bioavailability of iCo-019 (Oral Amphotericin B). Subjects were randomized into one of 4 cohorts dosed sequentially at 100 mg, 200 mg, 400 mg and 800 mg. Each cohort consisted of eight (8) subjects where six (6) subjects were randomized to receive the Investigational Product (IP) and two (2) subjects were randomized to receive Placebo.
The safety profile for each subject dosed in each of the first three cohorts was reviewed by the Safety Review Committee (SRC) before proceeding to a higher dose. With the conclusion of recruitment, safety will be assessed for all subjects in addition to pharmacokinetic profiles.
Amphotericin B is an approved drug for the treatment of fungal and parasitic conditions but the current leading formulation is an intravenous infusion. iCo Therapeutics is developing a proprietary oral formulation to increase convenience and market application.
We currently expect results from the Phase 1 study in early July 2018.
Phase 2 Bertilimumab Trial
On May 15, 2018 our licensee announced positive Phase 2 data for the treatment of moderate-to-extensive bullous pemphigoid. iCo Therapeutics is eligible to receive up to $32M in potential future milestone payments. For more information please refer to:
www.immunepharma.com/immune-pharmaceuticals-presents-updated-positive-results-from-phase-2-trial-of-bertilimumab-in-bullous-pemphigoid/
About iCo Therapeutics
iCo Therapeutics identifies existing development stage assets for use in underserved ocular and infectious diseases. Such assets may exhibit utility in non-ophthalmic conditions outside the Company's core focus areas and if so the Company will seek to capture further value via partnerships, such as its license with Immune Pharmaceuticals IMNP, -0.38% which is in several Phase 2 studies involving iCo-008. iCo shares trade on the TSX Venture Exchange under the symbol "ICO" and on the OTCQB under the symbol "ICOTF".
For more information, visit the Company website at: www.icotherapeutics.com.
No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Andrew Rae, CEO778-772-7775rae@icotherapeutics.com
copyright (c) newsfile corp. 2018
EnviroLeach Announces Closing of Private Placement and Investment Banking Agreement with Roth Capital Partners
Fri, Mar 2, 2018 6:34 pm
EnviroLeach Technologies (Newsletter@enviroleach.com)
VANCOUVER, British Columbia, March 02, 2018 — EnviroLeach Technologies Inc. (the “Corporation“ or “EnviroLeach”), (CSE:ETI) (OTCQB:EVLLF) (FSE:7N2), is pleased to announce that, further to its press release of February 27, 2018, it has completed its brokered and non-brokered private placement offering of 6,700,000 units (each, a “Unit”) at a subscription price of CAD$1.50 per Unit, representing total gross proceeds of CAD$10,050,000. The brokered private placement was completed pursuant to a Placement Agency Agreement between the Corporation and Roth Capital Partners.
Each Unit consists of one common share in the capital of the Corporation and one common share purchase warrant (each, a “Warrant”). Each Warrant entitles the holder to purchase one common share in the capital of the Corporation (a “Warrant Share”) at a price of CAD$2.50 at any time prior to 4:30 pm (Vancouver time) on March 1, 2020. The expiry date of the Warrants will be subject to acceleration as follows: If at any time after July 2, 2018, the closing price (or closing bid price on days when there are no trades) of the common shares on the Canadian Securities Exchange exceeds CAD$3.00 for 10 consecutive trading days, then, upon the Corporation sending Warrantholders notice of acceleration of the expiry date and issuing a news release announcing such accelerated expiry date, the Warrants will only be exercisable for a period of 30 days following the date on which notice is sent to the Warrantholders.
The securities issued in connection with this private placement will be subject to a hold period under Canadian securities legislation which will expire on July 2, 2018.
In respect of the brokered portion of the private placement, the Corporation has paid Roth Capital Partners a placement fee of CAD$608,000 in cash, and issued to Roth Capital Partners 405,333 compensation warrants (each, a “Compensation Warrant”). Each Compensation Warrant will entitle the holder to purchase one unit (consisting of one common share and one common share purchase warrant) at the private placement offering price of CAD$1.50 per unit, and will be exercisable until March 1, 2020, including by way of cashless exercise. Each underlying common share purchase warrant will be subject to substantially the same terms as are applicable to the Warrants, except that, subject to acceleration, they will also expire on March 1, 2020, and contain a cashless exercise provision.
The Corporation intends to use the proceeds from the private placement for general working capital and to continue the development of its technologies.
The Corporation is also pleased to announce that it has entered into a one-year investment banking agreement with Roth Capital Partners (www.roth.com), a relationship-driven investment bank focused on serving emerging growth companies and their investors.
The securities referred to in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements. This news release does not constitute an offer for sale of securities for sale, nor a solicitation for offers to buy any securities.
About EnviroLeach Technologies Inc.
EnviroLeach Technologies is a technology company and near-term gold producer that is engaged in the development and commercialization of environmentally-friendly formulas and technologies for the treatment of materials in the mining and E-Waste sectors. Using its proprietary non-cyanide, water-based, near neutral pH treatment process, EnviroLeach extracts precious metals from ores, concentrates, and E-Waste using only FDA approved additives to ambient temperature water.
Contact Information:
EnviroLeach Technologies Inc.
Duane Nelson
President & CEO
info@EnviroLeach.com
Great chart Georgie18 - I got in EVLLF at .77, looking sweet!
Session maybe changing his mind.. check out the link.
This link may have been posted here already, for those of you that haven't seen it ENJOY!
http://fortune.com/video/2017/01/10/watch-sen-jeff-sessions-discuss-marijuana-legalization/
You tube video of Blumenaeur speaking against Sessions! He is in the house speaking on these issues and says Sessions moves will cause a speed up better marijuana reform laws. SESSIONS, The Keelber Elf is a LOSER!
Jeff Sessions is nothing but a Big Tobacco Leach & a stupid bumpkin that should retire! Fed crack down would only cost broke states like CA more money... besides the Fed would loose and get slammed in court with all the jury members that voted to legalize cannabis! Sessions the Keebler Elf and the Fed, are LOSERS in this game! GO TRTC GO!
Buy on the pull backs, nothing got up all the time! Take advantage of the dips it what I do!
Terra Tech +17% as California grants temporary license to sell cannabis
Jan. 2, 2018 3:58 PM ET|About: Terra Tech Corp. (TRTC)|By: Carl Surran, SA News Editor
Terra Tech (OTCQX:TRTC +17.1%) skyrockets to 52-week highs after saying it has received temporary authorization from the state of California to cultivate, non-volatile manufacture, distribute and retail cannabis.
TRTC says it will begin adult-use cannabis sales to the California market immediately through its Blüm retail dispensaries located in Oakland and Santa Ana.
TRTC says the move gives it a "first mover advantage [that] will enable us to grow our brand and gain traction with new customers in what is expected to be the nation's largest cannabis market."
Blum approved to sell recreational in Santa Ana.
https://www.google.com/amp/s/www.ocregister.com/2017/12/30/santa-ana-dispensaries-get-ok-to-sell-marijuana-to-adults-with-just-an-id-on-new-years-day/amp/
Forget that PooBear punk Murph! I am up HUGE on TRTC! The $1.50 high of 2014 may be realized in 2018! Long n Strong!
It has doubled since the golden cross in late January. 15 pennies was a gift!
Nice up move today, need some mews to keep the momo going!
Like the golden cross last month...would like to see the price move a lot higher with more news.
Put the crack pipe down... $10 is possible near term!
SUTR chart looks interesting; we could see a breakout over a buck IMO. Closed at the HOD @ 0.85
Look for PLKI and AAPL to rip higher in August!
AAPL is a screaming buy and so is PLKI; look for PLKI and AAPL to rip higher in August!
Do you guys think GERN will reach a new 52 wk high once FDA full hold is lifted? I am thinking the shorts will be crushed and a new high could be reached easily when that news hits the wire!!!
All in good time; MRNA is very undervalued at 70 cents imo!